Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

le metabolic effects in healthy subjects, together with the safety profile observed to date, suggest that LX4211 could be considered earlier in the diabetes treatment paradigm, perhaps including the potential treatment of pre-diabetes in patients with impaired glucose tolerance or impaired fasting glucose (IGT/IFG)."

About the Clinical Trial

The clinical trial was designed to assess the effect of different LX4211 dose schedules relative to meal time  in healthy subjects when taken as a single daily dose (400 mg) or a split dose (200 mg twice daily).  Subjects were randomized to LX4211 in an ordered sequence to assess the pharmacodynamic effects of different dosing times, ranging from 1 hour prior to meals to immediately prior to meals.  Pharmacodynamic effects, include urinary glucose excretion, fasting plasma glucose, insulin, PYY and GLP-1 (total and active) were assessed at multiple time points during the 12-day dosing period.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing o
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Roche,s Bloodhound technology ... market segment in hematology testing, according to Kalorama ... recent unveiling of its Bloodhound digital cell imaging ... m 511 hematology analyzer – is notable ... enjoyed by current leader CellaVision, but also compete ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/n7kzjb/vitamin_d_market ) has ... Analog, Application, End-User & by Region - Global Trends & ... This market is projected to reach about $2.5 Million by ... and rising opportunities in countries such as India ... , and Brazil . In 2013, ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... BiPar Sciences, Inc., a,privately held biopharmaceutical ... demonstrating that BSI-401 inhibited pancreatic cancer,cell growth ... and in combination with,oxaliplatin. BSI-401 is BiPar,s ... therapies known as PARP (poly-ADP-ribose polymerase) inhibitors. ...
... share updates about sleep apnea and sleep behavior,disorders, ... offered updates about diagnosing and treating patients with ... and sleep,behavior disorders, at CHEST 2007, the annual ... Chicago on Oct. 20-25. The following are,brief summaries ...
Cached Medicine Technology:BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
(Date:7/3/2015)... , ... July 03, 2015 , ... Scientists at several ... to mesothelioma with even minimal asbestos exposure. Click here to read the complete ... University of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed ...
(Date:7/3/2015)... LENEXA, Kan. (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... Buffalo, NY (PRWEB) , ... July 03, 2015 ... ... Noonday Learning Lecture took place on June 25, 2015 at 1:00pm. The Association ... presentation explored issues pertaining to injured bicyclists and practical points of investigating these ...
(Date:7/3/2015)... ... , ... Talcum powder attorneys representing clients in national lawsuits announce the launch ... website. Just as the previous version did, the new website will serve as a ... ovarian cancer warning information. The site is routinely updated with news articles on talcum ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the largest ... MD as the new Medical Director of its Frisco facility. , “We are pleased ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3
... the number of episodes, study finds, , , WEDNESDAY, Jan. 28 ... who suffer from urinary incontinence, losing weight might just ease ... Jan. 29 issue of the New England Journal of ... 8 percent of their body weight -- an average of ...
... and evaluated at The Medical College of Wisconsin to ... has been one of eight chosen by the Centers ... The 2008 Compendium of Evidence-based HIV Prevention Interventions. To ... HIV or STD-related risk behaviors, or promote safer behaviors. ...
... Conference Call Scheduled for February 23 HAYWARD, Calif., ... SLTM ), a global leader in the medical aesthetics ... quarter ended December 31, 2008 and provided financial goals ... expected to be in the range of $9.3 million ...
... later physical health, study says , , WEDNESDAY, Jan. ... a long-lasting impact on children,s health, U.S. researchers ... teens who,d experienced either typical or extremely stressful ... an orphanage. Specifically, the researchers looked at levels ...
... oral health and tooth-related books to the children in attendance. Each ... proper tooth brushing techniques and the importance of dental health. ... ... Delta Dental of Minnesota ,s Tooth Fairy will be visiting area ...
... 28 Patrick Cobb, M.D., a community-based,oncologist in Billings, ... (COA), a national advocacy group for cancer patients and,professionals. ... to be chosen to lead COA for the next ... Centers of the Northern,Rockies in Billings, Montana. "Community cancer ...
Cached Medicine News:Health News:Weight Loss Helps Incontinence 2Health News:Weight Loss Helps Incontinence 3Health News:Medical College of Wisconsin recognized for AIDS intervention research 2Health News:Solta Medical, Inc. Announces Preliminary Financial Results for the Fourth Quarter of 2008 2Health News:Solta Medical, Inc. Announces Preliminary Financial Results for the Fourth Quarter of 2008 3Health News:Solta Medical, Inc. Announces Preliminary Financial Results for the Fourth Quarter of 2008 4Health News:Childhood Stress Compromises Immune System 2Health News:Delta Dental of Minnesota's Tooth Fairy to Visit Iron Range Area Classrooms 2Health News:Delta Dental of Minnesota's Tooth Fairy to Visit Iron Range Area Classrooms 3Health News:Dr. Patrick Cobb Named President of Community Oncology Alliance 2
... Marco could offer you a choice of two ... Chart Projector uses a halogen bulb for longer ... use. The Marco Chart Projector offers a lower ... includes a thermistor for extended bulb life. And ...
... Only Marco could offer you a choice ... The EverLight Chart Projector uses a halogen bulb ... under typical use. The Marco Chart Projector offers ... system that includes a thermistor for extended bulb ...
... The Ultra Series features a modernized optical ... which transmits light more efficiently, producing a ... clarity. The breakthrough optical quality of the ... increase in light transmission, a 15% expanded ...
With the touch of a button, the Marco Encore Automatic Chair quickly reclines from an upright position to a fully horizontal, flat-table mode-or anywhere in between....
Medicine Products: